Innova Biosciences installs colloidal gold bulk production capability
Bulk production facility enables company to support large diagnostics customers.
Innova Biosciences has announced the installation of bulk production capability for its colloidal gold nanoparticle products. The move enables the company to support any scale of operation, including the largest players in the diagnostics field.
Innova’s ultra-high quality colloidal gold nanoparticles have a consistent uniform shape and size, ensuring reliability and reproducibility, and overcoming potential issues around product aggregation caused by particles with irregular shapes. Innova’s colloidal gold also demonstrates high efficiency antibody binding, for maximum sensitivity. The range is available in high gold concentrations, to simplify assay development.
The company has recently significantly expanded its production facilities at its headquarters in Cambridge, UK, which includes the added colloidal gold production capability, In addition, Innova has taken a further 2500 sq ft of office space at the South Cambridge Business Park, which will be occupied by its sales and marketing team.
Dr Nick Gee, CEO of Innova Biosciences, commented: “Innova is committed to supporting all customers with the same high level of service and consistency in quality, from academic researchers through to bulk manufacturing scientists.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.